wolfy casino no deposit bonus “Gladiator II” asks the question: Are you not moderately entertained for roughly 60% of this sequel? Truly, this is a movie dependent on managed expectations and a forgiving attitude toward its tendency to overserve. More of a thrash-and-burn schlock epic than the comparatively restrained 2000 “Gladiator,” also directed by Ridley Scott, the new one recycles a fair bit of the old one’s narrative cries for freedom while tossing in some digital sharks for the flooded Colosseum and a bout of deadly sea-battle theatrics. They really did flood the Colosseum in those days, though no historical evidence suggests shark deployment, real or digital. On the other hand (checks notes), “Gladiator II” is fiction. Screenwriter David Scarpa picks things up 16 years after “Gladiator,” which gave us the noble death of the noble warrior Maximus, shortly after slaying the ignoble emperor and returning Rome to the control of the Senate. Our new hero, Lucius (Paul Mescal), has fled Rome for Numidia, on the North African coast. The time is 200 A.D., and for the corrupt, party-time twins running the empire (Joseph Quinn and Fred Hechinger), that means invasion time. Pedro Pascal takes the role of Acacius, the deeply conflicted general, sick of war and tired of taking orders from a pair of depraved ferrets. The new film winds around the old one this way: Acacius is married to Lucilla (Connie Nielsen, in a welcome return), daughter of the now-deceased emperor Aurelius and the love of the late Maximus’s life. Enslaved and dragged to Rome to gladiate, the widower Lucius vows revenge on the general whose armies killed his wife. But there are things this angry young phenom must learn, about his ancestry and his destiny. It’s the movie’s worst-kept secret, but there’s a reason he keeps seeing footage of Russell Crowe from the first movie in his fever dreams. Battle follows battle, on the field, in the arena, in the nearest river, wherever, and usually with endless splurches of computer-generated blood. “Gladiator II” essentially bumper-cars its way through the mayhem, pausing for long periods of expository scheming about overthrowing the current regime. The prince of all fixers, a wily operative with interests in both managing gladiators and stocking munitions, goes by the name Macrinus. He’s played by Denzel Washington, who at one point makes a full meal out of pronouncing the word “politics” like it’s a poisoned fig. Also, if you want a masterclass in letting your robes do a lot of your acting for you, watch what Washington does here. He’s more fun than the movie but you can’t have everything. The movie tries everything, all right, and twice. Ridley Scott marshals the chaotic action sequences well enough, though he’s undercut by frenetic cutting rhythms, with that now-familiar, slightly sped-up visual acceleration in frequent use. (Claire Simpson and Sam Restivo are the editors.) Mescal acquits himself well in his first big-budget commercial walloper of an assignment, confined though he is to a narrower range of seething resentments than Crowe’s in the first film. I left thinking about two things: the word “politics” as savored/spit out by Washington, and the innate paradox of how Scott, whose best work over the decades has been wonderful, delivers spectacle. The director and his lavishly talented design team built all the rough-hewn sets with actual tangible materials the massive budget allowed. They took care to find the right locations in Morocco and Malta. Yet when combined in post-production with scads of medium-grade digital effects work in crowd scenes and the like, never mind the sharks, the movie’s a somewhat frustrating amalgam. With an uneven script on top of it, the visual texture of “Gladiator II” grows increasingly less enveloping and atmospherically persuasive, not more. But I hung there, for some of the acting, for some of the callbacks, and for the many individual moments, or single shots, that could only have come from Ridley Scott. And in the end, yes, you too may be moderately entertained. “Gladiator II” — 2.5 stars (out of 4) MPA rating: R (for strong bloody violence) Running time: 2:28 How to watch: Premieres in theaters Nov. 21. Michael Phillips is a Tribune critic.

What's On Tap in Chicago Bulls news ? Welcome to the 55th edition of "Tasting Flight," a daily newsletter to keep fans updated on all the latest news in Bulls Nation. Patrick Williams Trade Possibilities Sunday's edition of the Bulls On Tap Tasting Flight featured reporting on the Bulls being open to trading forward Patrick Williams. If they decide to move on, what could a deal look like? On Tap Sports Net's Alejandro Delgado mocked up three trades taking into account the Bulls' and potential suitors' needs. Defense Will Be Optional in Washington As the Bulls prepare to visit the Washington Wizards on Tuesday, Chicago Sports Network's K.C. Johnson shared ugly defensive rankings for both squads. Defensive ranks for Tuesday’s NBA Cup matchup in Washington D.C. Defensive rating: Bulls 28th, Wizards 30th Opponent points per game: Bulls 30th, Wizards 29th Opponent FG%: Bulls 30th, Wizards 24th Lonzo Ball , Julian Phillips Injury Updates Johnson also reported that Lonzo Ball will travel with the Bulls on their two-game road trip and Julian Phillips was cleared to return to practice. Lonzo Ball will travel on two-game trip and Billy Donovan, who witnessed Ball’s workout today, said he’s encouraged by Ball’s progress. Julian Phillips, who missed last game due to illness, returned to practice. Happy Birthday Talen Horton-Tucker ! Bulls guard Talen Horton-Tucker celebrates his 24th birthday on Nov. 25, 2024. Happy Birthday, THT! pic.twitter.com/G6sFj39rOp This article first appeared on On Tap Sports Net and was syndicated with permission.NoneA Russian man arrested in October for operating a travel agency for gay customers was found dead in his Moscow cell while in pretrial detention, the OVD-Info rights group said on December 29. The group quoted the lawyer of Andrei Kotov, 48, as saying the man had died by suicide in his cell, although the report cannot independently be confirmed. Kotov was director of the Men Travel agency, and was facing charges of "organizing extremist activity and participating in it." Russia in recent years has intensified its relentless crackdown on LGBT rights, often accusing suspects of extremist activities. To read the original story by Current Time, click here . Azerbaijani President Ilham Aliyev has accused Russia of trying to hide the cause of a deadly plane crash this week, calling on Moscow to admit responsibility. The Azerbaijan Airlines passenger plane was flying from the Azerbaijani capital, Baku, to Grozny in Russia's Chechnya region on December 25 when it was diverted and crashed in Kazakhstan, killing 38 of the 67 people on board. There has been growing evidence that the jet was hit by a Russian air-defense missile in Chechnya before it went down near the city of Aqtau in western Kazakhstan. Aliyev said the plane was mistakenly shot down while approaching Grozny, adding that the jet's GPS systems were affected by electronic jamming. "Our plane was hit by accident," Aliyev told state television on December 29. "Therefore, admitting the guilt, apologizing in a timely manner to Azerbaijan, which is considered a friendly country, and informing the public about this -- all these were measures and steps that should have been taken." "Unfortunately, for the first three days, we heard nothing from Russia except for some absurd theories," added Aliyev, citing statements in Russia that attributed the crash to birds or the explosion of some sort of gas cylinder on the plane. Those theories, Aliyev said, showed "that the Russian side wanted to cover up the issue." Aliyev's comments came a day after Russian President Vladimir Putin apologized to Aliyev but did not accept blame for the plane crash. In a phone call with Aliyev, Putin said Russian air defenses were repelling an alleged Ukrainian drone attack on Grozny when the plane was trying to land at the airport there, a Kremlin statement said. Putin "conveyed his apologies in connection with the fact that the tragic incident occurred in Russian airspace," the statement said, indicating that Putin acknowledged the plane was damaged over Chechnya but stopped short of stating a Russian missile strike was the cause. Russia's Investigative Committee has opened a criminal investigation into the possible violation of flight safety rules, the statement said. It said two Azerbaijani prosecutors were working with Russian law enforcement in Grozny and that Russian, Azerbaijani, and Kazakh authorities were working together at the crash site in Kazakhstan. The Kremlin statement is likely to further increase suspicions that a Russian missile damaged the Embraer-190 jet before it was diverted to Aktau, across the Caspian Sea from Chechnya, where it crashed near the shore after a steep descent and burst into flames. Evidence of a missile strike includes footage of damage inside the plane before the crash and images of the hole-pocked tail section after the crash, as well as comments from survivors who said they heard at least one explosion outside the plane over Chechnya. Azerbaijani lawmaker Hikmat Babaoghlu told RFE/RL on December 27 that there is a "very strong" possibility that the plane was damaged by a Russian air-defense missile. He said that the "observations and conclusions drawn so far support the idea that the plane being shot down is the closest to the truth." TBILISI -- Mikheil Kavelashvili, a former soccer player and right-wing populist, has been sworn in as Georgia's new president amid a monthslong political crisis , likely further complicating the country's prospects for European Union membership. Outgoing President Salome Zurabishvili left her residence in the presidential palace in the capital, Tbilisi, on the same day but said she remained the legitimate head of state. The pro-Western Zurabishvili, whose term ended on December 29, had said she would not step down. She claimed her successor -- chosen by an electoral college dominated by the ruling Georgian Dream party -- is "illegitimate." Georgia has been the scene of anti-government protests since Georgian Dream claimed victory in October parliamentary elections that were marred by instances of vote-buying, double-voting, physical violence, and intimidation. The rallies intensified after a government decision last month to delay negotiations on the South Caucasus country joining the European Union. In a defiant speech to thousands of supporters outside the presidential palace on December 29, Zurabishvili said she remained the "only legitimate president" and vowed to continue to fight on. "This building was a symbol only as long as a legitimate president was sitting here," she said. "I take the legitimacy with me." Zurabishvili, who called for new parliamentary elections, called Kavelashvili's inauguration a "parody." Her remarks came moments after the 53-year-old Kavelashvili, a hard-line critic of the West, was formally sworn in during a ceremony in parliament. In his speech, Kavelashvili called for the country to unite behind him around "shared values, the principles of mutual respect, and the future we should build together." Kavelashvili has been known to make fiery anti-Western remarks in the past, although during his speech he stated that Georgians should "strengthen our country and move toward the European family." In 2016, he helped found the People's Power party, a more-radical offshoot of Georgian Dream. But he has remained close to the ruling party and has been criticized for his ties to Moscow-friendly billionaire Bidzina Ivanishvili, a former prime minister and founder of the Georgian Dream party, The presidency is a largely ceremonial post, but in the current tense political environment holds deeper symbolic meaning, and the departure of Zurabishvili could deepen Georgia's split with the West -- once the nation's closest backers. Several hundred protesters rallied outside the parliament building, with some holding up red cards in a gesture to Kavelashvili's soccer career. The demonstrators dispersed shortly afterward but vowed to rally again in the evening. The Interior Ministry said six protesters were detained outside the parliament building. Local media reported that several demonstrators were injured by police. A day earlier, Zurabishvili joined protesters in Tbilisi as rally participants waved Georgian and EU flags, played music, and marched along the Saarbruecken Bridge in the capital to form a "chain of unity." The rally marked one month since the start of the recent wave of protests, which have been met with violent police action, injuries, and mass arrests by Georgian authorities. Protesters accuse the Georgian Dream-led government of moving the country away from the EU and tilting closer to Russia. A U.S. State Department spokesperson on December 29 told RFE/RL in e-mailed comments that the United States is closely monitoring the situation in Georgia. The spokeperson added that respect for the freedoms of expression and peaceful assembly are critical to a functioning society. On December 27, the United States said it had slapped fresh sanctions on Ivanishvili for undermining Georgia's democracy for the "benefit of the Russian Federation." "Under Ivanishvili's leadership, Georgian Dream has advanced the interests of the Kremlin by derailing Georgia’s Euro-Atlantic trajectory -- in direct contradiction to what was envisioned by the Georgian people and the Georgian Constitution," U.S. Secretary of State Antony Blinken said. The action prompted anger from the Georgian Dream party, while the Georgian opposition hailed the action and called on the EU to also move against Ivanishvili and other Georgian leaders. Dutch Foreign Minister Caspar Veldkamp said in an X post on December 29 that he commends Zurabishvili "for her vital leadership and unwavering commitment to Georgia's European course." "For a month now, Georgian people are peacefully defending their democratic and European future in the streets despite violence and intimidation," he said, adding that the Georgian government should "restore public trust" and "consider possible new elections." Zurabishvili -- who has spilt with the government and backed the protesters early in the wave of rallies -- had called on Georgian Dream to set a date for new parliamentary elections by December 29. In another show of Western support, U.S. Republican House member Joe Wilson on December 27 wrote on X that he welcomed the new sanctions and added that he had invited Zurabishvili -- "as the only legitimate leader in Georgia" -- to Donald Trump's presidential inauguration on January 20. Georgia received EU candidate status in December 2023, but ties with Brussels have been tense in recent months following the adoption in May of a controversial "foreign agent" law pushed through parliament by Georgian Dream, which has been in power since 2012. Russia's state energy giant Gazprom on December 28 said it would cease gas deliveries to Moldova at the end of this year because of a dispute over debt with the small Balkan nation that is aligned with the West. Moldovan Prime Minister Dorin Recean condemned Gazprom's decision, describing it as "an oppressive tactic" through which Russia "uses energy as a political weapon" and said he would pursue international legal means to fight it. The head of Moldovagaz said that, as early as December 2022, the entire volume of gas supplied by Gazprom was intended for the Moscow-backed separatist region, Transdniester , located on the left bank of the Dniester River. To read the original story by RFE/RL’s Moldovan Service, click here . Drone attacks and fighting intensified in Ukraine and Russia on December 28, while Ukrainian President Volodymyr Zelenskiy accused Slovakia's prime minister of taking "orders" from the Kremlin to harm Kyiv and his own people as an energy feud heightened as well. "It appears that [Russian President Vladimir] Putin gave [Robert] Fico the orders to open the second energy front against Ukraine at the expense of the Slovak people's interests," Zelenskiy wrote on social media. "Fico's threats to cut off Ukraine's emergency power supply this winter while Russia attacks our power plants and energy grid can only be explained by this." The comments came after Fico on December 27 threatened to halt supplies of electricity to Ukraine if Kyiv blocks transit of Russian gas to Slovakia. Ukraine has announced it will not extend the transit contract of Russian state-owned company Gazprom after January 1 -- ceasing deliveries of gas to several European nations -- as the West looks to cut off the Kremlin's source of funding for the war. The transport deal was signed before Russia's full-scale invasion of Ukraine began in February 2022, and most European nations have since begun developing alternative sources of gas, although Fico says finding alternatives would be too costly for Slovakia. Fico, along with Hungarian leader Viktor Orban, has angered the West by continuing to have close ties to Putin despite U.S. and EU sanctions. Fico visited Putin in Moscow earlier this week and has offered to host potential peace talks between Ukraine and Russia. Zelenskiy said Slovakia accounts for nearly 20 percent of Ukraine's power imports. "Slovakia is part of the single European energy market and Fico must respect common European rules," Zelenskiy wrote. "Any arbitrary decisions in Bratislava or Moscow's orders to Fico regarding electricity cannot cut Ukraine's power supply, but they can certainly cut current Slovak authorities' ties to the European community," he added, suggesting the move would deprive Slovakia itself of some $200 million a year. Meanwhile, as Russia's full-scale invasion grinds on toward its fourth year, Ukraine and Russia exchanged accusations of drone attacks in several regions as battlefield clashes intensified along the front lines, with the "hottest" fighting reported around the embattled Ukrainian city of Pokrovsk. Russian air defenses destroyed 56 drones overnight, the Defense Ministry said on December 28. It said 28 drones were shot down in the Rostov region, 17 in the Voronezh region, and 11 in the Belgorod region, where local officials reportedly said two residents of a village were injured by shrapnel from a blast. The Russian claims could not be independently verified. A Russian occupation official said on Telegram that four people were wounded in what he said was a Ukrainian drone attack that hit a car in the Russian-held city of Nova Kakhovka in Ukraine’s Kherson region early in the morning. In Mykolayiv, the Ukrainian-held capital of a region adjacent to Kherson, the military said Ukrainian defenders had neutralized all 16 drones launched by Russia on December 28. "Of the 16 UAVs launched, 15 were shot down, another one was a simulator. All 15 were shot down in the Mykolaiv region," the Ukrainian Air Force said Earlier, a Russian drone attack in the city caused fires on the roof of a five-story residential building and on the grounds of a commercial enterprise, regional governor Vitaliy Kim said on Telegra. He said that nobody was hurt, and that the military had destroyed 12 drones over the region overnight . Russia and Ukraine have used drones regularly since Russia launched the full-scale invasion of its neighbor in February 2022. There are mounting suspicions that the crash of a Azerbaijan Airlines passenger jet earlier this week near Aqtau, Kazakhstan, that killed 38 of the 67 people aboard was caused by Russian air-defense systems on alert for Ukrainian drone attacks on the Chechnya region, where the jet was due to land in Grozny before it was diverted across the Caspian Sea. Ukraine said its forces struck a "protected facility" of the Russian military in the Oryol region near the border with Ukraine. It said the target was a warehouse holding Iranian-made Shahed drones. Also on December 28, the Russian Federal Security Service (FSB) claimed it had thwarted a plot to kill a high-level Russian military officer and an unnamed Russian “war blogger” who writes about the invasion. The FSB, whose claim could not be independently verified, said it had arrested a Russian man it said was acting under instructions from Ukrainian military intelligence. It said it had found a cache outside Moscow with an improvised explosive device camouflaged as a stereo speaker. There was no immediate comment from Ukraine on the FSB claim, which came 11 days after the general who headed Russia's Nuclear, Biological, and Chemical Defense Forces (RKhBZ) was killed, along with an assistant, by a bomb concealed in a scooter. A source at Ukraine's SBU security service told RFE/RL that the blast that killed Lieutenant General Igor Kirillov and his assistant was the result of a special operation by the Ukrainian agency. In the United States, White House spokesman John Kirby on December 27 said Washington has reports of North Korean soldiers fighting alongside Russian troops "taking their own lives rather than surrendering to Ukrainian forces." He said the action was "likely out of fear of reprisal against their families in North Korea in the event that they’re captured. " In a video address, Zelenskiy had said "several" North Korean soldiers -- badly wounded in fighting alongside Russian forces -- have died after being captured by Ukrainian troops on the battlefield. Zelenskiy said, without providing details, that Kyiv had reports of North Korean "enforcers" executing wounded soldiers to prevent them being captured alive by Ukrainian forces. Western sources estimate that 12,000 North Korean troops are in Russia's Kursk region, parts of which are occupied by Ukrainian forces amid ongoing pitched battles and reports of heavy losses. Germany's foreign minister described the suspected sabotage of a Baltic Sea power cable as a "wake-up call" for the West and urged the European Union to impose new sanctions targeting what is known as Russia's " shadow fleet ." Meanwhile, a media outlet focusing on shipping news and intelligence reported that the ship suspected of damaging the cable linking Finland and Estonia on December 25 was equipped with "special transmitting and receiving devices that were used to monitor naval activity." The Eagle S "had transmitting and receiving devices installed that effectively allowed it to become a 'spy ship' for Russia," Lloyd's List reported on December 27, citing "a source familiar with the vessel who provided commercial maritime services to it as recently as seven months ago." Finland seized the Eagle S on December 26, citing suspicions that it caused an outage of the Estlink 2 undersea power cable and damaged four Internet lines. Finnish investigators said the ship may have caused the damage by dragging its anchor along the sea floor. Finnish and EU officials say the Eagle S is believed to belong to a "shadow fleet" of old, uninsured oil vessels used to bypass Western sanctions and maintain a source of revenue for Russia's economy and its war against Ukraine. The poor condition of these ships has also raised concerns about environmental disasters. "The suspected vessel is part of Russia’s shadow fleet, which threatens security and the environment , while funding Russia's war budget," the European Commission said on December 26, suggesting the incident was part of a deliberate effort to damage "critical infrastructure" in Europe. "We will propose further measures, including sanctions, to target this fleet." In comments on December 28, German Foreign Minister Annalena Baerbock urged "new European sanctions against the Russian shadow fleet," which she said is "a major threat to our environment and security" that is used by Russia "to finance its war of aggression in Ukraine." "Almost every month, ships are damaging major undersea cables in the Baltic Sea," Baerbock said in a statement to the Funke media group. "Crews are leaving anchors in the water, dragging them for kilometers along the seafloor for no apparent reason, and then losing them when pulling them up.” "It's more than difficult to still believe in coincidences," she said. "This is an urgent wake-up call for all of us." TBILISI -- On the eve of a potentially explosion day, Georgian President Salome Zurabishvili called for supporters to gather at the presidential palace on December 29 as she joined a mass rally against the Georgian Dream-led government’s moves to delay closer European Union integration. "Greetings from the Orbeliani Palace,” she said in a video released to social media. "I am here, I will be here, I will spend the night here as well." "Tomorrow, I will be waiting for you...at 10 a.m. -- and from here, I will tell you what tomorrow will be like. I will tell you what the following days will be like, and what the days of victory will be like." A potential showdown looms on the streets of Tbilisi on December 29 as Zurabishvili has vowed not to step down at the end of her term on that day, claiming her successor -- chosen by an electoral college dominated by Georgian Dream -- was "illegitimate." She joined protesters in the capital on December 28 as rally participants waved Georgian and EU flags, played music, and marched along the Saarbruecken Bridge in the capital to form a " chain of unity ." The rally marked one month since the start of the recent wave of anti-government protests, which have been met with violent police action, injuries, and mass arrests by Georgian authorities. Protesters accuse the government of the Georgian Dream party of moving the country away from the EU and tilting closer to Moscow. The political crisis erupted after Georgian Dream claimed victory in October parliamentary elections that the Organization for Security and Cooperation in Europe (OSCE) said was marred by instances of vote-buying, double-voting, physical violence, and intimidation. The rallies intensified after a government decision last month to delay negotiations on Georgia joining the EU. On December 24, Human Rights Watch called for Georgian security forces to be investigated for the "brutal police violence" against largely peaceful protesters who have taken to the streets for the demonstrations. On December 27, the United States said it had slapped fresh sanctions on Russia-friendly billionaire Bidzina Ivanishvili, a former prime minister and the founder of the Georgian Dream party, for undermining Georgia's democracy for the "benefit of the Russian Federation." "Under Ivanishvili's leadership, Georgian Dream has advanced the interests of the Kremlin by derailing Georgia’s Euro-Atlantic trajectory -- in direct contradiction to what was envisioned by the Georgian people and the Georgian Constitution," U.S. Secretary of State Antony Blinken said. The action prompted anger from the Georgian Dream party, while the Georgian opposition hailed the action and called on the EU to also move against Ivanishvili and other Georgian leaders. Zurabishvili -- who has spilt with the government and backed the protesters early in the wave of rallies -- on December 22 called on Georgian Dream to set a date for new parliamentary elections by December 29. In a show of Western support, U.S. Republican House member Joe Wilson on December 27 wrote on X that he welcomed the new sanctions and added that he had invited Zurabishvili -- "as the only legitimate leader in Georgia" -- to Donald Trump's presidential inauguration on January 20. "I am in awe of her courage in the face of the assault by Ivanishvili and his friends" in China and Iran, Wilson added, without mentioning Russia. Earlier this month, an electoral college dominated by Georgian Dream chose Mikheil Kavelashvili, a 53-year-old former soccer player and right-wing populist, as Georgia's next president. His inauguration is supposed to take place on December 29, though the 72-year-old Zurabishvili, whose term ends this year, has said she will not step down, setting up the potentially tense showdown. "Next week at this time, I will be president," Zurabishvili restated on December 27. Georgia received EU candidate status in December 2023, but ties with Brussels have been tense in recent months following the adoption in May of a controversial "foreign agent" law pushed through parliament by Georgian Dream, which has been in power since 2012. Afghanistan's Taliban-led government said Taliban forces targeted what it claimed were "centers and hideouts for malicious elements" it said were involved in a recent attack in Afghanistan, as an upsurge of cross-border fighting continues. The statement from the Taliban's Defense Ministry followed reports of deadly early morning clashes on December 28 between Taliban forces and Pakistani border guards. It came days after the government said Pakistani aircraft bombed targets in Afghanistan in an attack it said killed dozens of civilians. The ministry gave few details about the strikes, which it said were launched against targets in several districts behind the "hypothetical line" -- a reference to a portion of the border with Pakistan that Afghan authorities have long disputed. Local sources told RFE/RL's Radio Azadi that three people in Paktia Province were killed and two wounded by gunfire from Pakistani border guards, and that clashes also took place in the Khost province. The reports could not be independently verified. There was no immediate comment from the Pakistani government. But the head of a community in the Kurram district told RFE/RL's Radio Mashaal that Taliban forces fired rockets at two security posts near the border at about 6 a.m., setting off fighting that continued for several hours. The Taliban's Defense Ministry suggested the strikes on Pakistan were retaliation for what the Taliban-led government said were Pakistani air strikes that killed 46 civilians in Paktika Province, which also borders Pakistan, on December 24. Pakistan says that militants from the Islamist group Tehrik-e Taliban Pakistan (TTP) are hiding across the border in Afghanistan, and Islamabad has repeatedly asked the Afghan Taliban to take action against them. The Afghan Taliban say the TTP is in Pakistan. There has been a steady increase in TTP attacks in Pakistan’s northwestern Khyber Pakhtunkhwa Province since the Taliban returned to power in Kabul in August 2021 following the withdrawal of U.S.-led forces from Afghanistan. Authoritarian ruler Alyaksandr Lukashenka extended a wave of pardons ahead of a January presidential election in Belarus, ordering the release of 20 prisoners jailed on extremism charges his opponents and rights groups say were politically motivated. Lukashenka's press service suggested the pardons were issued on humanitarian grounds, saying 14 of those ordered released have chronic illnesses and 10 of them have children. It said 11 of the 20 are women. The press service claimed the prisoners had all sought pardons and expressed remorse, an assertion that could not be independently verified. It said that authorities would "monitor their behavior following their release." Since July, Lukashenka has pardoned more than 225 people whom activists consider political prisoners. Rights groups have recognized nearly 3,600 people as political prisoners since the state launched a massive crackdown when pro-democracy protests erupted after Lukashenka, in power since 1994, claimed a landslide victory in an August 2020 election that millions believe was stolen though fraud . Many of those have served out their sentences. Ahead of a January 26 election in which he is certain to be awarded a new term, Lukashenka may be seeking to signal to the West that he is easing off on the persistent clampdown that the state has imposed since the 2020 election. But the crackdown continues, with frequent arrests and trials on what activists say are politically motivated charges. At least 1,253 people whom rights groups consider political prisoners remain behind bars, and the real number is believed to be higher. Lukashenka has roped Belarus closely to Russia and has provided support for Russia's war on neighboring Ukraine, including by allowing Russian forces to invade from Belarusian territory, and he says Russian nuclear weapons have been deployed in Belarus. But over 30 years in power, he has often tried to capitalize on Belarus’ position between Russia in the east and NATO and the European Union to the west and north. Russian President Vladimir Putin has apologized over the crash of an Azerbaijan Airlines passenger plane this week, the Kremlin said, amid growing evidence that the jet was hit by a Russian air-defense missile in the Chechnya region before it went down in Kazakhstan, killing 38 of the 67 people on board. In a phone call with Azerbaijani President Ilham Aliyev, Putin said Russian air defenses were repelling an alleged Ukrainian drone attack on Chechnya’s capital, Grozny, when the plane was trying to land at the airport there, a Kremlin statement said. Putin "conveyed his apologies in connection with the fact that the tragic incident occurred in Russian airspace," the statement said, indicating that Putin acknowledged the plane was damaged over Chechnya but stopped short of stating a Russian missile strike was the cause. "In the conversation, it was noted that...the aircraft tried more than once to approach the Grozny airport for landing," it said, adding that “at this time, Ukrainian combat drones were attacking Grozny [and the nearby cities of] Mozdok and Vladikavkaz, and Russian air-defense systems were repelling these attacks." Russia's Investigative Committee has opened a criminal investigation into the possible violation of flight safety rules, the statement said. It said two Azerbaijani prosecutors were working with Russian law enforcement in Grozny and that Russian, Azerbaijani, and Kazakh authorities were working together at the crash site near Aqtau, Kazakhstan. The Kremlin statement is likely to further increase suspicions that a Russian missile damaged the Embraer-190 jet before it was diverted to Aktau, across the Caspian Sea from Chechnya, where it crashed near the shore after a steep descent and burst into flames. Evidence of a missile strike includes footage of damage inside the plane before the crash and images of the hole-pocked tail section after the crash, as well as comments from survivors who said they heard at least one explosion outside the plane over Chechnya. Azerbaijani lawmaker Hikmat Babaoghlu told RFE/RL on December 27 that there is a "very strong" possibility that the plane was damaged by a Russian air-defense missile. He said that the "observations and conclusions drawn so far support the idea that the plane being shot down is the closest to the truth." On the same day, White House spokesman John Kirby said U.S. experts "have seen some early indications that would certainly point to the possibility that this jet was brought down by Russian air-defense systems." Reuters quoted an Azerbaijani source familiar with the investigation as saying results indicated the plane was hit by a Pantsir-S air-defense system, a self-propelled antiaircraft gun and missile system designed by Russia. The crash has disrupted air traffic in the Caucasus and beyond. An Azerbaijan Airlines flight bound for the Russian spa town of Mineranlye Vody, not far from Grozny, took off from Baku on December 27 but then abruptly headed back after receiving a flight information notice that Russian airspace it was due to fly through was closed. Azerbaijan Airlines later said it is suspending flights to several Russian cities, including Mineralnye Vody, Sochi, Volgograd, Ufa, Samara, Grozny, and Makhachkala. Turkmenistan Airlines announced on December 28 that it was canceling all its flights between the capital, Ashgabat, and Moscow from December 30 to January 31, giving no reason for the decision. Turkmenistan borders Kazakhstan on the eastern shore of the Caspian. Also on December 28, Russia’s aviation authority, Rosaviatsia, said that restrictions were briefly placed on the operation of the airport in the Tatarstan regional capital, Kazan, to ensure flight safety, and media reports said that all departures and arrivals had been suspended. Flights heading to Kazan from the Siberian cities of Tomsk, Surgut, and Kemerovo were redirected to an airfield in Nizhnekamsk, Russian state news agency TASS reported, citing the airport's press service. No specific reason was given for the measures, which Rosaviatsia said had been lifted a few hours later. Russia has closed airports at times due to alleged drone attacks, and a drone attack hit high-rise buildings in Kazan on December 21. NATO has said it would bolster its presence in the Baltic Sea after undersea power lines and Internet cables were damaged by suspected sabotage believed to be carried out by vessels belonging to Russia’s so-called “ shadow fleet .” Estonia also announced on December 27 that it had begun a naval operation to guard a crucial electricity line in the Baltic Sea in coordination with allies as tensions mounted in the region. NATO Secretary-General Mark Rutte said in a social media post following discussions with Finnish President Alexander Stubb that "NATO will enhance its military presence in the Baltic Sea." Both Finland and Estonia have coastlines on the Baltic Sea. When asked for details about planned actions, NATO officials told AP that the alliance “remains vigilant and is working to provide further support, including by enhancing our military presence” in the region. "We have agreed with Estonia, and we have also communicated to NATO Secretary-General Mark Rutte, that our wish is to have a stronger NATO presence," Stubb told a news conference. Stubb added that investigators did not want to jump to conclusions, but a day earlier he had said that "it is necessary to be able to prevent the risks posed by ships belonging to the Russian 'shadow fleet.'" The "shadow fleet" is a reference to old, uninsured oil vessels typically used to bypass Western sanctions on Russia and maintain a source of revenue. European government and the United States have accused Russia of intensifying "hybrid attacks" following reports of damage to Baltic Sea communications cables, although they have not yet directly tied Moscow to the damage. NATO stepped up monitoring critical infrastructure in the Baltic following Russia's full-scale invasion of Ukraine in 2022 and the destruction of the Nord Stream natural gas pipeline seven months later. Chinese-linked ships have also been suspected of sabotaging undersea infrastructure over recent years. Sweden -- NATO's newest member, which also has a coastline on the Baltic Sea -- said its coast guard had stepped up surveillance of sea traffic and had deployed aircraft and vessels in concert with regional allies. The European Commission on December 26 said a cargo ship suspected of having deliberately damaged power and Internet cables in the Baltic Sea was part of Russia's "shadow fleet." The poor condition of these ships has also raised concerns about environmental disasters. Finnish authorities on December 26 boarded and took command of the Cook Islands-registered Eagle S oil tanker in the Baltic Sea as part of its investigation into the damages, saying it likely belong to the "shadow fleet." Investigators have said the damage could have been caused by the ship intentionally dragging its anchor. The Kremlin said it had no connection to the ship seized by Finland. It has regularly denied that it is involved in any of the many incidents involving Baltic Sea region infrastructure assets. The United States said it has slapped fresh sanctions on Russia-friendly billionaire Bidzina Ivanishvili, a former prime minister and the founder of the ruling Georgian Dream party, for undermining Georgia's democracy for the "benefit of the Russian Federation." "Under Ivanishvili's leadership, Georgian Dream has advanced the interests of the Kremlin by derailing Georgia’s Euro-Atlantic trajectory -- in direct contradiction to what was envisioned by the Georgian people and the Georgian Constitution," U.S. Secretary of State Antony Blinken said in a statement on December 27. Blinken added that "Ivanishvili and Georgian Dream's actions have eroded democratic institutions, enabled human rights abuses, and curbed the exercise of fundamental freedoms in Georgia." "We strongly condemn Georgian Dream's actions under Ivanishvili's leadership, including its ongoing and violent repression of Georgian citizens, protesters, members of the media, human rights activists, and opposition figures." The new measures will block transactions involving entities owned by Ivanishvili, the statement said. According to Bloomberg News, Ivanishvili's fortune is estimated at $7.5 billion, much of it coming through metals, banking, and telecom assets in Russia during the 1990s. Prime Minister Irakli Kobakhidze called the U.S. action "blackmail" and said it was Ivanishvili's "reward" for protecting Georgia's national interest. However, opposition leader Giorgi Vashadze of the Unity National Movement hailed the U.S. decision, according to Georgia's Interpress news agency. "I welcome this step from the United States and believe that we are quickly moving toward victory and will celebrate Georgia without Ivanishvili, who is the bringer of chaos and misery to this country," he was quoted as saying. In a previous action, the United States on December 12 said it would "prohibit visa issuance to those who are responsible for, or complicit in, undermining democracy in Georgia." That move affected some 20 people, "including individuals serving as government ministers and in parliament, law enforcement and security officials, and private citizens," it said in a statement , without naming the individuals. Georgia, once a closer U.S. ally, has angered Washington and the European Union with its perceived tilt toward Russia and its violent crackdown on dissent in the Caucasus nation. The sanctions come at a crucial time, as Georgia's fate hangs in the balance -- whether it will intensify its tilt toward Moscow, return to the pro-Europe path, or remain in an environment of unrest and uncertainty. Police in Tbilisi have clashed with pro-West protesters over the past several weeks, detaining dozens and injuring scores of people who accuse the government of the Georgian Dream party of moving the country away from the European Union and closer to Moscow. The political crisis erupted after Georgian Dream claimed victory in October parliamentary elections that the Organization for Security and Cooperation in Europe (OSCE) said was marred by instances of vote-buying, double-voting, physical violence, and intimidation. The rallies intensified after a government decision last month to delay negotiations on Georgia joining the EU. The New York-based Human Rights Watch (HRW) on December 24 called for Georgian security forces to be investigated for the “brutal police violence” against largely peaceful protesters who have taken to the streets for huge anti-government demonstrations. Georgian President Salome Zurabishvili – who has spilt with the government and backed the protesters -- on December 22 called on Georgian Dream to set a date for new parliamentary elections by December 29. "Next week at this time I will be president," Zurabishvili restated on December 27. U.S. Republican House member Joe Wilson wrote on X that he welcomed the new sanctions and added that he had invited Zurabishvili -- "as the only legitimate leader in Georgia" -- to Donald Trump's presidential inauguration on January 20 "I am in awe of her courage in the face of the assault by Ivanishvili and his friends" in China and Iran, Wilson added, without mentioning Russia. Earlier this month, an electoral college dominated by Georgian Dream chose Mikheil Kavelashvili, a 53-year-old former soccer player and right-wing populist, as Georgia's next president. His inauguration is supposed to take place on December 29, though the 72-year-old Zurabishvili, whose term ends this year, has said she will not step down, setting up a potentially explosive showdown. Georgia received EU candidate status in December 2023, but ties with Brussels have been tense in recent months following the adoption in May of a controversial "foreign agent" law pushed through parliament by Georgian Dream, which has been in power since 2012. PODGORICA -- After a multinational back-and-forth legal battle, Montenegro on December 27 said it would extradite South Korean cryptocurrency entrepreneur Hyeong Do Kwon -- the so-called Crypto King -- to the United States. Do Kwon is sought by both the United States and South Korea and also faces possible legal action in Singapore. Montenegrin courts have previously issued at least eight often-contradictory decisions regarding Do Kwon's fate. In September, the Montenegrin Supreme Court ruled that Do Kwon could be sent to either the United States or South Korea and that the final decision on which country would be up to Justice Minister Bojan Bozovic. On December 24, Do Kwon lost his final appeal against extradition with Montenegro's Constitutional Court. In the latest ruling, the Justice Ministry said the U.S. request had met the threshold for removal and, as a result Bozovic "issued a decision approving the extradition." The ministry said the criteria included the gravity of the criminal acts, the order of submission of the extradition requests, and the citizenship of the person in question. The former CEO and co-founder of the cryptocurrency company Terraform Labs is wanted by U.S. and South Korean authorities for his alleged role in capital market and securities fraud involving assets worth some $40 billion. Do Kwon was arrested with business partner Chang Joon in March 2023 at Podgorica airport while attempting to fly to Dubai using on allegedly forged passports. They each received a four-month prison sentence on the forged-passport charge. Chang, who was wanted only by South Korea, was extradited to that country on February 5. After serving his sentence, Do Kwon was sent to a shelter for foreigners near Podgorica, where he awaited extradition. Do Kwon in October claimed that the South Korean charges were illegitimate and "politically motivated." Despite the legal struggle, Do Kwon's trial in absentia took place in the United States, where a New York jury on April 5 found him and Terraform labs liable on civil fraud charges, agreeing with the U.S. Securities and Exchange Commission that they had misled investors. Terraform Labs agreed to pay about $4.5 billion in a civil settlement with the SEC following the court's ruling. Do Kwon was ordered to pay $204 million. Following the verdict, a Terraform spokesperson said, "We continue to maintain that the SEC does not have the legal authority to bring this case at all" and that the company was weighing its options. Italy’s Foreign Ministry said journalist Cecilia Sala, who was in Iran to carry out "journalistic activities," has been detained by Tehran police authorities. The ministry said in a statement on December 27 that Sala, who has a podcast called Stories that covers life in places around the world, was detained on December 19. It gave no reason for the detention, but said in a statement that the ambassador from Italy's embassy in Tehran had paid a consular visit "to verify the conditions and state of detention of Sala." "The family was informed of the results of the consular visit. Previously, Sala had the opportunity to make two phone calls with her relatives," it said. Sala posted a podcast from Tehran on December 17 about patriarchy in the Iranian capital. Iran is routinely accused of arresting dual nationals and Western citizens on false charges to use them to pressure Western countries. Earlier this month, Reza Valizadeh , a dual U.S.-Iranian citizen and former journalist for RFE/RL's Radio Farda, was handed a 10-year sentence by Tehran's Revolutionary Court on charges of "collaborating with a hostile government." Valizadeh resigned from Radio Farda in November 2022 after a decade of work. He returned to Iran in early 2024 to visit his family but was arrested on September 22. His two court sessions, held on November 20 and December 7, reportedly lacked a prosecution representative, with the judge assuming that role. Sources close to the journalist claim he fell into a "security trap" despite receiving unofficial assurances from Iranian security officials that he would not face legal troubles upon returning to Iran. Iran is among the most repressive countries in terms of freedom of the press. Reporters Without Borders ranked Iran 176th out of 180 countries in its 2024 World Press Freedom Index. The Paris-based media watchdog says Iran is now also one of the world’s biggest jailers of journalists. An Azerbaijani lawmaker said there is a "very strong" possibility that the crash of a passenger jet earlier this week was caused by Russian air-defense systems on alert for Ukrainian drone attacks. Speculation has mounted that the Azerbaijan Airlines plane, which was headed from Baku to Grozny, the capital of Russia’s Chechnya region, may have been hit by an air-defense missile before crossing the Caspian Sea and crashing near Aqtau, Kazakhstan, killing 38 passengers and crew. Lawmaker Hikmat Babaoghlu told RFE/RL's Azerbaijani Service in an interview on December 27 that such an explanation is most likely "closest to the truth." "This is only a possibility, but a very strong one, and the observations and conclusions drawn so far support the idea that the plane being shot down is the closest to the truth," he said. "In this specific case, the incident involves Azerbaijan's airliner being damaged within the territory of the Russian Federation, with the event causing the crash occurring there. Therefore, there is no doubt that responsibility falls on the Russian Federation. If these assumptions are correct, accountability also undoubtedly rests with Russia," he added. Kazakh experts arrived on December 27 to examine the crash site and black box of the ill-fated passenger jet, as speculation -- and evidence -- mounted suggesting that a Russian air-defense missile may have inadvertently struck the craft. Even as the probe intensifies, countries with victims aboard the plane -- Azerbaijan, Kazakhstan, Russia, and Kyrgyzstan -- continue to mourn their dead and treat the injured from the crash of the Embraer 190 aircraft. Since the crash, uncertainty has rocked the aviation industry throughout the Caucasus. An Azerbaijan Airlines flight bound for the Russian spa town of Mineranlye Vody took off from Baku on December 27 but then abruptly headed back after receiving a flight information notice that Russian airspace it was due to fly through was closed . Azerbaijan Airlines later said it is suspending flights to several Russian cities, including Mineralnye Vody, Sochi, Volgograd, Ufa, Samara, Grozny, and Makhachkala. Speculation has swirled around the tragedy, with some experts pointing to holes seen in the plane's tail section as a possible sign that it could have come under fire from Russian air-defense systems engaged in thwarting Ukrainian drone attacks. White House spokesman John Kirby told reporters on December 27 that the United States has seen signs suggesting that the jet could have been hit by Russian air defense systems. U.S. experts "have seen some early indications that would certainly point to the possibility that this jet was brought down by Russian air defense systems," he said. Kirby added that Washington has “offered our assistance...should they need it" to the ongoing investigation being conducted by Azerbaijan and Kazakhstan. Evidence, yet to be corroborated by authorities, includes footage from inside the plane before the crash, images of the hole-pocked tail section after the crash, a survivor's comments, and accounts indicating there was a suspected drone attack around the time the plane apparently tried to land in Grozny. Reuters quoted an Azerbaijani source familiar with the investigation as saying results indicated the plane was hit by a Pantsir-S air-defense system, a self-propelled antiaircraft gun and missile system designed by Russia. It was not immediately clear where the black box would be examined. The process can be highly technical, and not all countries have the resources to undertake such work. Gulag Aslanli, a leader of Azerbaijan's opposition Musavat party, told RFE/RL that an international commission was needed to investigate the incident. "Russia cannot be allowed there," he said. "If the black box is going to be taken to Russia and examined there, I will look at its outcome with suspicion." Officials said it typically takes about two weeks to fully assess a black box, although various conditions can alter that time frame. Commenting on unconfirmed reports that the plane may have been shot down by a missile, Kazakh Senate Speaker Maulen Ashimbaev said it was "not possible" to say what may have damaged the aircraft until the investigation is finished. "Real experts are looking at all this, and they will make their conclusions. Neither Kazakhstan, Russia, nor Azerbaijan, of course, is interested in hiding information, so it will be brought to the public," Ashimbaev said. Kremlin spokesman Dmitry Peskov made a similar comment, reiterating Moscow's previous stance on the deadly incident. "An investigation is under way, and until the conclusions of the investigation, we do not consider we have the right to make any comments and we will not do so," Peskov told reporters on December 27. Russia's Interfax news agency quoted Russian officials as saying the plane, commissioned in 2013, had passed a maintenance check in October and that the pilot had "vast experience" with more than 15,000 flying hours. Azerbaijan Airlines President Samir Rzayev also told reporters the plane had been fully serviced in October and that there was no sign of technical malfunction. But he said it was too early to determine a cause: "The plane has been found with a black box. After detailed research, all aspects will be clear." The airline suspended flights along the route of the crash pending completion of the investigation. Azerbaijan's Prosecutor-General's Office said that "all possible scenarios are being examined." As the first seven survivors arrived back in the country on December 26, Azerbaijan observed a national day of mourning. Burials of four of those who lost their lives were conducted during the day, with additional funerals expected in the coming hours and days. Officials in Baku said the wounded arrived on a special flight arranged by Azerbaijan's Emergency Affairs Ministry and that the injured, many with severe burn wounds, were accompanied by medical professionals. Ayhan Solomon, Azerbaijan’s chief consul in Aqtau, told reporters that 26 of those killed were Azerbaijani citizens. He said 16 Azerbaijani citizens survived. “Of those, 10 to 12 are in good condition and others remain critically stable,” he added. Azerbaijan Airlines' supervisory board said on December 26 that the families of those killed will be compensated with 40,000 manats ($23,460), while those injured would receive 20,000 manats ($11,730). Along with the 42 Azerbaijani citizens, those aboard Flight J2-8243 were listed as 16 Russian nationals, six from Kazakhstan, and three Kyrgyz citizens, officials said. The survivors include nine Russian citizens, who were flown to Moscow on December 26 by the Russian Emergency Situations Ministry. Three of the Russian survivors were in critical condition, according to Russian health authorities. KYIV -- Ukrainian President Volodymyr Zelenskiy said “several” North Korean soldiers – badly wounded in fighting alongside Russian forces – have died after being captured by Ukrainian troops on the battlefield and he accused Moscow of having little regard for their survival. Zelenskiy, echoing earlier remarks by U.S. officials, said soldiers sent to Russia by Pyongyang are suffering major losses in fighting in Russia's Kursk region. The Ukrainian leader accused Moscow and North Korean “enforcers” of leaving the soldiers unprotected in battle and even executing fighters to prevent them from being captured alive. He did not provide evidence to back up the claims and they could not independently be verified. The North Korean military has suffered “many losses. A great deal. And we can see that the Russian military and the North Korean enforcers have no interest in the survival of these Koreans at all,” he said in a video address on December 27. “Everything is arranged in a way that makes it impossible for us to capture the Koreans as prisoners – their own people are executing them. There are such cases. And the Russians send them into assaults with minimal protection.” He said Ukrainian soldiers had managed to take some prisoners. "But they were very seriously wounded and could not be saved.” The remarks came after South Korea’s National Intelligence Service said that a North Korean fighter had died of wounds suffered before his capture by Ukrainian special operations troops in the Kursk region. "We have confirmed through an allied intelligence agency that a North Korean soldier who was captured on the 26th died a little while ago due to serious injuries," the news release said. On December 26, the Ukrainian news outlet Militarnyi said a soldier believed to be North Korean had been captured by Ukrainian Special Operations Forces in the Kursk region. A photo of a captured soldier, who is believed to have been injured, also was previously shared on Telegram. The photo has not been independently verified. Details about the soldier's condition and status are not known. Last month Pyongyang ratified a "comprehensive strategic partnership" agreement with Russia, cementing a deal that paved the way for its soldiers to fight on Russian soil against Ukraine. Western sources estimate that 12,000 North Korean troops are in the Kursk region, parts of which are occupied by Ukrainian forces amid ongoing pitched battles. U.S. Response White House spokesman John Kirby told reporters on December 27 that North Korean forces are suffering heavy casualties on the front lines, adding that some 1,000 of their troops have been killed or wounded in the Kursk region over the past week. "It is clear that Russian and North Korean military leaders are treating these troops as expendable and ordering them on hopeless assaults against Ukrainian defenses," Kirby said. Kirby said also U.S. President Joe Biden would likely approve another package of military aid for Kyiv in the coming days as he bids to bolster Ukraine’s forces before leaving office on January 20. U.S. officials later told reporters that a new package of military assistance worth $1.25 billion is scheduled to be announced on December 30. North Korean Losses Zelenskiy on December 23 said more than 3,000 troops, or about a quarter of the North Korean special forces sent to Russia, had been killed or injured, though he couched his statement by saying the data was preliminary. South Korea’s National Intelligence Service reported on a lower figure, saying on December 19 that about 1,100 North Korean special forces have been killed or injured in Russia since entering the fray against Ukraine. On December 15, Skhemy (Schemes), an investigative unit of RFE/RL's Ukrainian Service, received photos from Ukrainian military sources purportedly showing the bodies of dead soldiers in Kursk, including what was said to be North Korean fighters. RFE/RL has not been able to independently verify the claims. Russia has not commented on the report. North Korean military support is coming at a critical time in the war. Russia is seeking to overpower an undermanned and under-resourced Ukrainian infantry and gain territory before its own manpower and resources become constrained. Russia has lost more than 600,000 soldiers in the nearly three-year war, the Pentagon said in early October. It has burned through so much war material that it is struggling to replace its artillery and missile needs amid sweeping Western sanctions. Now nearly two-thirds of the mortars and shells Russia launches at Ukraine come from North Korea, the Wall Street Journal reported , citing Andriy Kovalenko, a Ukrainian Army officer. And every third ballistic missile was made in North Korea, Ukrainian officials said. The European Commission said a cargo ship suspected of having deliberately damaged power and Internet cables in the Baltic Sea is part of Russia's so-called "shadow fleet," prompting the EU to threaten new sanctions against Moscow. "We strongly condemn any deliberate destruction of Europe’s critical infrastructure," the commission said in a statement on December 26. "The suspected vessel is part of Russia’s shadow fleet, which threatens security and the environment, while funding Russia’s war budget. We will propose further measures, including sanctions, to target this fleet," the statement added. The statement added that "in response to these incidents, we are strengthening efforts to protect undersea cables, including enhanced information exchange, new detection technologies, as well as in undersea repair capabilities, and international cooperation." The remarks come after two fiber-optic cables owned by Finnish operator Elisa linking Finland and Estonia were broken on December 25. A third link between the two countries -- owned by China's Citic -- was damaged, authorities said. An Internet cable running between Finland and Germany belonging to Finnish group Cinia was also believed to have been severed, according to officials. Investigators said the damage could have been caused by the ship intentionally dragging its anchor. Finnish authorities on December 26 boarded and took command of the Cook Islands-registered Eagle S oil tanker in the Baltic Sea as part of the investigation. The Finnish customs service said the Eagle S is believed to belong to Russia's so-called “shadow fleet” of old, uninsured oil vessels used to bypass Western sanctions and maintain a source of revenue. The poor condition of these ships has also raised concerns about environmental disasters. Finnish President Alexander Stubb also suggested the cargo has Russian links and that his country is closely monitoring the situation. "It is necessary to be able to prevent the risks posed by ships belonging to the Russian shadow fleet," Stubb wrote on X . EU foreign ministers on December 16 adopted a package of sanctions against Moscow targeting tankers transporting Russian oil as the bloc looked to curb the circumvention of previous measures aimed at hindering Kremlin's ability to wage war against Ukraine. Meanwhile, NATO chief Mark Rutte said on December 26 that the alliance is ready to help Finland and Estonia as they launch their probe into the possible "sabotage." "Spoke with [Estonian Prime Minister] Kristen Michal about reported possible sabotage of Baltic Sea cables,” he wrote on X. “NATO stands in solidarity with Allies and condemns any attacks on critical infrastructure. We are following investigations by Estonia and Finland, and we stand ready to provide further support." Russian President Vladimir Putin said on December 26 that Slovak Prime Minister Robert Fico is ready to offer a “platform” for possible peace talks between Moscow and Kyiv to end the war in Ukraine. Putin told the media Fico said during a recent meeting that "if there are any negotiations, [the Slovaks] would be happy to provide their country as a platform." Most terms suggested so far by Putin have been deemed unacceptable to Ukrainian President Volodymyr Zelenskiy. Fico is one of the few European leaders Putin has stayed friendly with since Moscow launched its full-scale invasion of Ukraine in 2022, prompting criticism of the Slovak leader by Zelenskiy and many Western leaders. To read the original story by RFE/RL's Russian Service, click here . Iranian President Masud Pezeshkian is scheduled to travel to Russia on January 17, state-controlled media in Iran and Russia reported on December 26. Quoting Iranian Ambassador to Moscow Kazem Jalali, Iran's Tasnim news agency said that “the president will visit Russia on January 17 and a cooperation agreement between the two countries will be signed during the visit." Russia and Iran both are under severe financial sanctions imposed by Western nations and have stepped up bilateral cooperation on many fronts in recent years. The West has accused Iran of providing weapons to Russia for use against Ukraine. Tehran has denied the allegations despite evidence widespread use of Iranian-made drones in the war. SARAJEVO -- Bosnia-Herzegovina’s security minister has been arrested on charges of money-laundering, abuse of office, and accepting bribes, the Balkan nation’s prosecutor’s office said. The minister, Nenad Nesic, was among seven people arrested on similar charges, the office said on December 26. The charges stem from an investigation by the Bosnian state prosecutor and the Interior Ministry of Bosnia's ethnic-Serb entity, Republika Srpska, into suspected corruption at the Roads of RS (Putevi RS) public company, where Nesic was general manager from 2016 to 2020. The company's current general manager, Milan Dakic, was also among those arrested, prosecutors said. The company did not immediately comment. Nesic, 46, has been Bosnia’s security minister since 2022. When asked by reporters about the case as he was entering an East Sarajevo police station, Nesic said only that "I continue to fight for Republika Srpska," according to Reuters. Nesic is president of the Democratic People's Alliance (DNS), which is in a coalition with Milorad Dodik's Alliance of Independent Social Democrats (SNSD). Dodik, who is president of Republika Srpska, claimed on social media that this was an "unacceptable procedure" and a "persecution of cadres" from the Bosnian government. The pro-Russia Dodik is under sanctions imposed by the United States and Britain for his efforts to undermine the Dayton agreements that ended the 1992-95 Bosnian war. He is currently facing trial himself on charges he failed to comply with the decisions of international High Representative Christian Schmidt. Ethnic Serb lawmakers this week said Dodik's trial was political and based on illegal decisions by the high representative. They claimed that the court was unconstitutional because it was set up by Schmidt and not by the Dayton agreement. Since the Dayton peace accords were put into effect, the country has consisted of a Bosniak-Croat federation and the mostly ethnic Serb Republika Srpska under a weak central government, where Nesic holds the security portfolio. Israel carried out large-scale air strikes on the main airport in Yemen’s capital, Sanaa, on December 26 as it steps up attacks on the Iranian-backed Huthi rebels in what Tehran called a “violation” of peace and security. Huthi rebels said three people were killed and 14 were injured or missing following the Israeli attacks on the airport and other sites in Yemen, including port facilities. "Fighter jets conducted intelligence-based strikes on military targets belonging to the Huthi terrorist regime on the western coast and inland Yemen," the Israel Defense Forces (IDF) said. The attacks followed recent rocket launches by the Huthi fighters against the Tel Aviv area, although little damage was reported. The Iranian Foreign Ministry condemned the Israeli strikes on Yemen, calling them "aggressions" that it claimed were "a clear violation of international peace and security." It said they represented "an undeniable crime against the heroic and noble people of Yemen," who had "not spared any effort to support the oppressed people of Palestine." The Israeli military has said air strikes in Yemen are targeting Huthi sites that have been used to receive Iranian weapons, which are then often transported to other Tehran-linked groups in the Mideast -- mainly Hamas in Gaza and Hezbollah in Lebanon. Hamas has been designated a terrorist group by the United States and the European Union, while Hezbollah has also been deemed a terrorist group by Washington. The EU blacklists its military arm but not its political wing. The U.S. State Department designated the Huthis as a terrorist group at the start of this year. Hamas and Hezbollah have been severely weakened following massive Israeli military strikes on their respective sites in Gaza and Lebanon, and most of their leaders have been killed in Israel's military response to Hamas’s October 7, 2023, attack on Israel. Israeli Prime Minister Benjamin Netanyahu said the strikes would continue against the Huthi rebels, who have also targeted shipping in the Red Sea, claiming they are in solidarity of Hamas fighters in Gaza. "We are determined to cut this branch of terrorism from the Iranian axis of evil. We will continue until the job is done," Netanyahu said in a video statement. Tedros Adhanom Ghebreyesus -- head of the World Health Organization who was at the Sanaa airport during the Israeli attack -- said he was safe but that "one of our plane's crew members was injured.” A Pakistani military court has sentenced 60 people to prison terms ranging between two and 10 years over violent protests that erupted after the arrest of former Prime Minister Imran Khan in 2023, the army’s media wing said on December 26. The defendants, who included a relative of Khan as well as two retired military officers, were sentenced in connection with attacks on military facilities. Twenty-five other people were sentenced on the same charges on December 21. They have the right to appeal the sentences, the military’s media wing said in a statement. Protests erupted across Pakistan in May 2023 when Khan was arrested during his court appearance on corruption charges that he and his supporters deny. Thousands of Khan’s supporters ransacked military facilities and stormed government buildings. Several people were killed, and dozens were injured in the unrest. At least 1,400 protesters, including leaders of Khan’s Pakistan Tehrik-e-Insaf (PTI) party were arrested following the riots. But only 105 of those detained faced military trials. PTI condemned the sentencing, and said the court had violated the defendants’ rights. The United States expressed deep concern about the sentences, while Britain said that trying civilians in military courts "lacks transparency, independent scrutiny, and undermines the right to a fair trial.” The European Union said the sentences are "inconsistent with the obligations that Pakistan has undertaken under the International Covenant on Civil and Political Rights.” Kazakh experts are due to arrive on December 27 to examine the crash site and black box of the ill-fated Azerbaijan Airlines passenger jet, as speculation – and evidence – mounted suggesting that a Russian air defense missile may have inadvertently struck the craft. Even as the probe intensifies, countries with victims aboard the plane – Azerbaijan, Kazakhstan, Russia, and Kyrgyzstan -- continue to mourn their dead and treat the injured among the 67 passengers and crew who were aboard when the Embraer 190 aircraft fell from the sky on December 25. The plane went down on a scheduled flight from the Azerbaijani capital, Baku, to Grozny in Russia's Chechnya region after it was diverted and attempted an emergency landing near the city of Aqtau in western Kazakhstan, killing 38 and injuring 29, many with severe burns suffered in the flaming crash. Speculation swirled around the tragedy, with some experts pointing to holes seen in the plane’s tail section as a possible sign that it could have come under fire from Russian air defense systems engaged in thwarting Ukrainian drone attacks. A U.S. official, speaking on condition of anonymity, told news agencies that indications suggest a Russian antiaircraft system struck the airliner, although the official provided no details. Canada expressed concerns about reports that Russian air defenses may have caused the crash. "We call on Russia to allow for an open and transparent investigation into the incident and to accept its findings," the Canadian Global Affairs office said on X. Evidence, yet to be corroborated by authorities, includes footage from inside the plane before the crash, images of the planes hole-pocked tail section after the crash, a survivor’s comments, and accounts indicating that there was a suspected drone attack around the time the plane apparently tried to land in Grozny. Reuters quoted an Azerbaijani source familiar with the investigation as saying results indicated the plane was hit by a Pantsir-S air defense system, a self-propelled antiaircraft gun and missile system designed by Russia. It was not immediately clear where the black box would be examined. The process can be highly technical, and not all countries have the resources to undertake such work. Gulag Aslanli, a leader of Azerbaijan's opposition Musavat movement, told RFE/RL that an international commission was needed to investigate the incident. "Russia cannot be allowed there," he said. "If the black box is going to be taken to Russia and examined there, I will look at its outcome with suspicion." Talgat Lastaev, Kazakhstan's vice minister of transport, told RFE/RL that experts are scheduled to arrive at the site on December 27 to assess the next steps regarding the black box. Officials said it typically takes about two weeks to fully assess a black box, although various conditions can alter that time frame. Commenting on unconfirmed reports that the plane may have been shot down by a missile, Kazakh Senate Speaker Maulen Ashimbaev said it was “not possible” to say what may have damaged the aircraft until the investigation is finished. "Real experts are looking at all this and they will make their conclusions. Neither Kazakhstan, Russia, nor Azerbaijan, of course, is interested in hiding information, it will be brought to the public," Ashimbaev said. Kremlin spokesman Dmitry Peskov made a similar comment, saying: "We need to await the end of the investigation.” It was “wrong” to speculate before the investigators gave their findings, Peskov added. Russia's Interfax news agency quoted officials as saying the plane, commissioned in 2013, had passed a maintenance check in October and that the pilot had "vast experience," with more than 15,000 flying hours. Azerbaijan Airlines President Samir Rzayev also told reporters the plane had been fully serviced in October and that there was no sign of technical malfunction. But he said it was too early to determine a cause: "The plane has been found with a black box. After detailed research, all aspects will be clear." The airline suspended flights along the route of the crash pending completion of the investigation. Azerbaijani President Ilham Aliyev also said it was too early to determine a cause but at one point had suggested bad weather could have contributed to the crash. The office of Azerbaijan’s Prosecutor General said that "all possible scenarios are being examined." As the first seven survivors arrived back in the country on December 26, Azerbaijan observed a national day of mourning. Burials of four of those who lost their lives were conducted during the day, with additional funerals expected in the coming hours and days. National flags were flown at half-mast across Azerbaijan, and signals were sounded from vehicles, ships, and trains as the nation observed a moment of silence at noon to honor the victims of the plane crash. Officials in Baku said the wounded arrived on a special flight arranged by Azerbaijan's Emergency Affairs Ministry and that the injured were accompanied by medical professionals. There was no immediate word on the condition of the injured, who were among 29 survivors from the crash, many of whom suffered severe burn wounds. Ayhan Solomon, Azerbaijan’s chief consul in Aqtau, told reporters that 26 of those killed were Azerbaijani citizens. He said initial reports indicate that 16 Azerbaijani citizens survived. “Of those, 10 to 12 are in good condition and others remain critically stable,” he added. Azerbaijan Airlines' supervisory board said on December 26 that the families of those killed will be compensated with 40,000 manats ($23,460), while those injured would receive 20,000 manats ($11,730). Along with the 42 Azerbaijani citizens, those aboard Flight J2-8243 were listed as 16 Russian nationals, six from Kazakhstan, and three Kyrgyz citizens, officials said. The survivors include nine Russian citizens, who were flown to Moscow on December 26 by the Russian Emergency Situations Ministry. Three of the Russian survivors were in critical condition, according to Russian health authorities. Kazakh Deputy Prime Minister Qanat Bozymbaev -- who is in charge of a special government commission to investigate the incident -- said many of those who died in the crash were not immediately identifiable due to massive burns suffered. Bozymbaev said the 29 survivors had injuries ranging from moderate to severe, with many also suffering from major burns. According to Kazakhstan’s Health Ministry, the injured included at least two children and 11 people had been placed in intensive care.

Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’

By BILL BARROW, Associated Press PLAINS, Ga. (AP) — Newly married and sworn as a Naval officer, Jimmy Carter left his tiny hometown in 1946 hoping to climb the ranks and see the world. Less than a decade later, the death of his father and namesake, a merchant farmer and local politician who went by “Mr. Earl,” prompted the submariner and his wife, Rosalynn, to return to the rural life of Plains, Georgia, they thought they’d escaped. The lieutenant never would be an admiral. Instead, he became commander in chief. Years after his presidency ended in humbling defeat, he would add a Nobel Peace Prize, awarded not for his White House accomplishments but “for his decades of untiring effort to find peaceful solutions to international conflicts, to advance democracy and human rights, and to promote economic and social development.” The life of James Earl Carter Jr., the 39th and longest-lived U.S. president, ended Sunday at the age of 100 where it began: Plains, the town of 600 that fueled his political rise, welcomed him after his fall and sustained him during 40 years of service that redefined what it means to be a former president. With the stubborn confidence of an engineer and an optimism rooted in his Baptist faith, Carter described his motivations in politics and beyond in the same way: an almost missionary zeal to solve problems and improve lives. Carter was raised amid racism, abject poverty and hard rural living — realities that shaped both his deliberate politics and emphasis on human rights. “He always felt a responsibility to help people,” said Jill Stuckey, a longtime friend of Carter’s in Plains. “And when he couldn’t make change wherever he was, he decided he had to go higher.” Carter’s path, a mix of happenstance and calculation , pitted moral imperatives against political pragmatism; and it defied typical labels of American politics, especially caricatures of one-term presidents as failures. “We shouldn’t judge presidents by how popular they are in their day. That’s a very narrow way of assessing them,” Carter biographer Jonathan Alter told the Associated Press. “We should judge them by how they changed the country and the world for the better. On that score, Jimmy Carter is not in the first rank of American presidents, but he stands up quite well.” Later in life, Carter conceded that many Americans, even those too young to remember his tenure, judged him ineffective for failing to contain inflation or interest rates, end the energy crisis or quickly bring home American hostages in Iran. He gained admirers instead for his work at The Carter Center — advocating globally for public health, human rights and democracy since 1982 — and the decades he and Rosalynn wore hardhats and swung hammers with Habitat for Humanity. Yet the common view that he was better after the Oval Office than in it annoyed Carter, and his allies relished him living long enough to see historians reassess his presidency. “He doesn’t quite fit in today’s terms” of a left-right, red-blue scoreboard, said U.S. Transportation Secretary Pete Buttigieg, who visited the former president multiple times during his own White House bid. At various points in his political career, Carter labeled himself “progressive” or “conservative” — sometimes both at once. His most ambitious health care bill failed — perhaps one of his biggest legislative disappointments — because it didn’t go far enough to suit liberals. Republicans, especially after his 1980 defeat, cast him as a left-wing cartoon. It would be easiest to classify Carter as a centrist, Buttigieg said, “but there’s also something radical about the depth of his commitment to looking after those who are left out of society and out of the economy.” Indeed, Carter’s legacy is stitched with complexities, contradictions and evolutions — personal and political. The self-styled peacemaker was a war-trained Naval Academy graduate who promised Democratic challenger Ted Kennedy that he’d “kick his ass.” But he campaigned with a call to treat everyone with “respect and compassion and with love.” Carter vowed to restore America’s virtue after the shame of Vietnam and Watergate, and his technocratic, good-government approach didn’t suit Republicans who tagged government itself as the problem. It also sometimes put Carter at odds with fellow Democrats. The result still was a notable legislative record, with wins on the environment, education, and mental health care. He dramatically expanded federally protected lands, began deregulating air travel, railroads and trucking, and he put human rights at the center of U.S. foreign policy. As a fiscal hawk, Carter added a relative pittance to the national debt, unlike successors from both parties. Carter nonetheless struggled to make his achievements resonate with the electorate he charmed in 1976. Quoting Bob Dylan and grinning enthusiastically, he had promised voters he would “never tell a lie.” Once in Washington, though, he led like a joyless engineer, insisting his ideas would become reality and he’d be rewarded politically if only he could convince enough people with facts and logic. This served him well at Camp David, where he brokered peace between Israel’s Menachem Begin and Epypt’s Anwar Sadat, an experience that later sparked the idea of The Carter Center in Atlanta. Carter’s tenacity helped the center grow to a global force that monitored elections across five continents, enabled his freelance diplomacy and sent public health experts across the developing world. The center’s wins were personal for Carter, who hoped to outlive the last Guinea worm parasite, and nearly did. As president, though, the approach fell short when he urged consumers beleaguered by energy costs to turn down their thermostats. Or when he tried to be the nation’s cheerleader, beseeching Americans to overcome a collective “crisis of confidence.” Republican Ronald Reagan exploited Carter’s lecturing tone with a belittling quip in their lone 1980 debate. “There you go again,” the former Hollywood actor said in response to a wonky answer from the sitting president. “The Great Communicator” outpaced Carter in all but six states. Carter later suggested he “tried to do too much, too soon” and mused that he was incompatible with Washington culture: media figures, lobbyists and Georgetown social elites who looked down on the Georgians and their inner circle as “country come to town.” Carter carefully navigated divides on race and class on his way to the Oval Office. Born Oct. 1, 1924 , Carter was raised in the mostly Black community of Archery, just outside Plains, by a progressive mother and white supremacist father. Their home had no running water or electricity but the future president still grew up with the relative advantages of a locally prominent, land-owning family in a system of Jim Crow segregation. He wrote of President Franklin Roosevelt’s towering presence and his family’s Democratic Party roots, but his father soured on FDR, and Jimmy Carter never campaigned or governed as a New Deal liberal. He offered himself as a small-town peanut farmer with an understated style, carrying his own luggage, bunking with supporters during his first presidential campaign and always using his nickname. And he began his political career in a whites-only Democratic Party. As private citizens, he and Rosalynn supported integration as early as the 1950s and believed it inevitable. Carter refused to join the White Citizens Council in Plains and spoke out in his Baptist church against denying Black people access to worship services. “This is not my house; this is not your house,” he said in a churchwide meeting, reminding fellow parishioners their sanctuary belonged to God. Yet as the appointed chairman of Sumter County schools he never pushed to desegregate, thinking it impractical after the Supreme Court’s 1954 Brown v. Board decision. And while presidential candidate Carter would hail the 1965 Voting Rights Act, signed by fellow Democrat Lyndon Johnson when Carter was a state senator, there is no record of Carter publicly supporting it at the time. Carter overcame a ballot-stuffing opponent to win his legislative seat, then lost the 1966 governor’s race to an arch-segregationist. He won four years later by avoiding explicit mentions of race and campaigning to the right of his rival, who he mocked as “Cufflinks Carl” — the insult of an ascendant politician who never saw himself as part the establishment. Carter’s rural and small-town coalition in 1970 would match any victorious Republican electoral map in 2024. Once elected, though, Carter shocked his white conservative supporters — and landed on the cover of Time magazine — by declaring that “the time for racial discrimination is over.” Before making the jump to Washington, Carter befriended the family of slain civil rights leader Martin Luther King Jr., whom he’d never sought out as he eyed the governor’s office. Carter lamented his foot-dragging on school integration as a “mistake.” But he also met, conspicuously, with Alabama’s segregationist Gov. George Wallace to accept his primary rival’s endorsement ahead of the 1976 Democratic convention. “He very shrewdly took advantage of his own Southerness,” said Amber Roessner, a University of Tennessee professor and expert on Carter’s campaigns. A coalition of Black voters and white moderate Democrats ultimately made Carter the last Democratic presidential nominee to sweep the Deep South. Then, just as he did in Georgia, he used his power in office to appoint more non-whites than all his predecessors had, combined. He once acknowledged “the secret shame” of white Americans who didn’t fight segregation. But he also told Alter that doing more would have sacrificed his political viability – and thus everything he accomplished in office and after. King’s daughter, Bernice King, described Carter as wisely “strategic” in winning higher offices to enact change. “He was a leader of conscience,” she said in an interview. Rosalynn Carter, who died on Nov. 19 at the age of 96, was identified by both husband and wife as the “more political” of the pair; she sat in on Cabinet meetings and urged him to postpone certain priorities, like pressing the Senate to relinquish control of the Panama Canal. “Let that go until the second term,” she would sometimes say. The president, recalled her former aide Kathy Cade, retorted that he was “going to do what’s right” even if “it might cut short the time I have.” Rosalynn held firm, Cade said: “She’d remind him you have to win to govern.” Carter also was the first president to appoint multiple women as Cabinet officers. Yet by his own telling, his career sprouted from chauvinism in the Carters’ early marriage: He did not consult Rosalynn when deciding to move back to Plains in 1953 or before launching his state Senate bid a decade later. Many years later, he called it “inconceivable” that he didn’t confer with the woman he described as his “full partner,” at home, in government and at The Carter Center. “We developed a partnership when we were working in the farm supply business, and it continued when Jimmy got involved in politics,” Rosalynn Carter told AP in 2021. So deep was their trust that when Carter remained tethered to the White House in 1980 as 52 Americans were held hostage in Tehran, it was Rosalynn who campaigned on her husband’s behalf. “I just loved it,” she said, despite the bitterness of defeat. Fair or not, the label of a disastrous presidency had leading Democrats keep their distance, at least publicly, for many years, but Carter managed to remain relevant, writing books and weighing in on societal challenges. He lamented widening wealth gaps and the influence of money in politics. He voted for democratic socialist Bernie Sanders over Hillary Clinton in 2016, and later declared that America had devolved from fully functioning democracy to “oligarchy.” Yet looking ahead to 2020, with Sanders running again, Carter warned Democrats not to “move to a very liberal program,” lest they help re-elect President Donald Trump. Carter scolded the Republican for his serial lies and threats to democracy, and chided the U.S. establishment for misunderstanding Trump’s populist appeal. He delighted in yearly convocations with Emory University freshmen, often asking them to guess how much he’d raised in his two general election campaigns. “Zero,” he’d gesture with a smile, explaining the public financing system candidates now avoid so they can raise billions. Carter still remained quite practical in partnering with wealthy corporations and foundations to advance Carter Center programs. Carter recognized that economic woes and the Iran crisis doomed his presidency, but offered no apologies for appointing Paul Volcker as the Federal Reserve chairman whose interest rate hikes would not curb inflation until Reagan’s presidency. He was proud of getting all the hostages home without starting a shooting war, even though Tehran would not free them until Reagan’s Inauguration Day. “Carter didn’t look at it” as a failure, Alter emphasized. “He said, ‘They came home safely.’ And that’s what he wanted.” Well into their 90s, the Carters greeted visitors at Plains’ Maranatha Baptist Church, where he taught Sunday School and where he will have his last funeral before being buried on family property alongside Rosalynn . Carter, who made the congregation’s collection plates in his woodworking shop, still garnered headlines there, calling for women’s rights within religious institutions, many of which, he said, “subjugate” women in church and society. Carter was not one to dwell on regrets. “I am at peace with the accomplishments, regret the unrealized goals and utilize my former political position to enhance everything we do,” he wrote around his 90th birthday. The politician who had supposedly hated Washington politics also enjoyed hosting Democratic presidential contenders as public pilgrimages to Plains became advantageous again. Carter sat with Buttigieg for the final time March 1, 2020, hours before the Indiana mayor ended his campaign and endorsed eventual winner Joe Biden. “He asked me how I thought the campaign was going,” Buttigieg said, recalling that Carter flashed his signature grin and nodded along as the young candidate, born a year after Carter left office, “put the best face” on the walloping he endured the day before in South Carolina. Never breaking his smile, the 95-year-old host fired back, “I think you ought to drop out.” “So matter of fact,” Buttigieg said with a laugh. “It was somehow encouraging.” Carter had lived enough, won plenty and lost enough to take the long view. “He talked a lot about coming from nowhere,” Buttigieg said, not just to attain the presidency but to leverage “all of the instruments you have in life” and “make the world more peaceful.” In his farewell address as president, Carter said as much to the country that had embraced and rejected him. “The struggle for human rights overrides all differences of color, nation or language,” he declared. “Those who hunger for freedom, who thirst for human dignity and who suffer for the sake of justice — they are the patriots of this cause.” Carter pledged to remain engaged with and for them as he returned “home to the South where I was born and raised,” home to Plains, where that young lieutenant had indeed become “a fellow citizen of the world.” —- Bill Barrow, based in Atlanta, has covered national politics including multiple presidential campaigns for the AP since 2012.SpareBank 1 Nord-Norge ( OTCMKTS:SPXXF – Get Free Report ) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 400 shares, an increase of 100.0% from the November 30th total of 200 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. SpareBank 1 Nord-Norge Price Performance Shares of SPXXF stock opened at $7.78 on Friday. SpareBank 1 Nord-Norge has a 12 month low of $7.78 and a 12 month high of $7.78. The business’s 50-day moving average price is $7.78 and its 200-day moving average price is $8.17. SpareBank 1 Nord-Norge Company Profile ( Get Free Report ) Featured Articles Receive News & Ratings for SpareBank 1 Nord-Norge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpareBank 1 Nord-Norge and related companies with MarketBeat.com's FREE daily email newsletter .Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’Ukraine war pushes Europe into a race to build up its defence base

Forthright and fearless, the Nobel Prize winner took pot-shots at former prime minister Tony Blair and ex-US president George W Bush among others. His death came after repeated bouts of illness in which images of the increasingly frail former president failed to erase memories of his fierce spirit. Democrat James Earl “Jimmy” Carter Jr swept to power in 1977 with his Trust Me campaign helping to beat Republican president Gerald Ford. Serving as 39th US president from 1977 to 1981, he sought to make government “competent and compassionate” but was ousted by the unstoppable Hollywood appeal of a certain Ronald Reagan. A skilled sportsman, Mr Carter left his home of Plains, Georgia, to join the US Navy, returning later to run his family’s peanut business. A stint in the Georgia senate lit the touchpaper on his political career and he rose to the top of the Democratic movement. But he will also be remembered for a bizarre encounter with a deeply disgruntled opponent. The president was enjoying a relaxing fishing trip near his home town in 1979 when his craft was attacked by a furious swamp rabbit which reportedly swam up to the boat hissing wildly. The press had a field day, with one paper bearing the headline President Attacked By Rabbit. Away from encounters with belligerent bunnies, Mr Carter’s willingness to address politically uncomfortable topics did not diminish with age. He recently said that he would be willing to travel to North Korea for peace talks on behalf of US President Donald Trump. He also famously mounted a ferocious and personal attack on Tony Blair over the Iraq war, weeks before the prime minister left office in June 2007. Mr Carter, who had already denounced George W Bush’s presidency as “the worst in history”, used an interview on BBC radio to condemn Mr Blair for his tight relations with Mr Bush, particularly concerning the Iraq War. Asked how he would characterise Mr Blair’s relationship with Mr Bush, Mr Carter replied: “Abominable. Loyal, blind, apparently subservient. “I think that the almost undeviating support by Great Britain for the ill-advised policies of President Bush in Iraq have been a major tragedy for the world.” Mr Carter was also voluble over the Rhodesia crisis, which was about to end during his presidency. His support for Robert Mugabe at the time generated widespread criticism. He was said to have ignored the warnings of many prominent Zimbabweans, black and white, about what sort of leader Mugabe would be. This was seen by Mr Carter’s critics as “deserving a prominent place among the outrages of the Carter years”. Mr Carter has since said he and his administration had spent more effort and worry on Rhodesia than on the Middle East. He admitted he had supported two revolutionaries in Mugabe and Joshua Nkomo, and with hindsight said later that Mugabe had been “a good leader gone bad”, having at first been “a very enlightened president”. One US commentator wrote: “History will not look kindly on those in the West who insisted on bringing the avowed Marxist Mugabe into the government. “In particular, the Jimmy Carter foreign policy... bears some responsibility for the fate of a small African country with scant connection to American national interests.” In recent years Mr Carter developed a reputation as an international peace negotiator. He won the Nobel Peace Prize in 2002 for his commitment to finding peaceful solutions to international conflicts, his work with human rights and democracy initiatives, and his promotion of economic and social programmes. Mr Carter was dispatched to North Korea in August 2008 to secure the release of US citizen Aijalon Mahli Gomes, who had been sentenced to eight years of hard labour after being found guilty of illegally entering North Korea. He successfully secured the release of Mr Gomes. In 2010 he returned to the White House to greet President Barack Obama and discuss international affairs amid rising tensions on the Korean peninsula. Proving politics runs in the family, in 2013 his grandson Jason, a state senator, announced his bid to become governor in Georgia, where his famous grandfather governed before becoming president. He eventually lost to incumbent Republican Nathan Deal. Fears that Mr Carter’s health was deteriorating were sparked in 2015 when he cut short an election observation visit in Guyana because he was “not feeling well”. It would have been Mr Carter’s 39th trip to personally observe an international election. Three months later, on August 12, he revealed he had cancer which had been diagnosed after he underwent surgery to remove a small mass in his liver. Mr Obama was among the well-wishers hoping for Mr Carter’s full recovery after it was confirmed the cancer had spread widely. Melanoma had been found in his brain and liver, and Mr Carter underwent immunotherapy and radiation therapy, before announcing in March the following year that he no longer needed any treatment. In 2017, Mr Carter was taken to hospital as a precaution, after he became dehydrated at a home-building project in Canada. He was admitted to hospital on multiple occasions in 2019 having had a series of falls, suffering a brain bleed and a broken pelvis, as well as a stint to be treated for a urinary tract infection. Mr Carter spent much of the coronavirus pandemic largely at his home in Georgia, and did not attend Joe Biden’s presidential inauguration in 2021, but extended his “best wishes”. Former first lady Rosalynn Carter, the closest adviser to Mr Carter during his term as US president, died in November 2023. She had been living with dementia and suffering many months of declining health. “Rosalynn was my equal partner in everything I ever accomplished,” Mr Carter said in a statement following her death. “She gave me wise guidance and encouragement when I needed it. As long as Rosalynn was in the world, I always knew somebody loved and supported me.”

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenImpressive news from a high-profile business partner was a major reason for the stock price pop experienced by SoundHound AI (NASDAQ: SOUN) on Thursday. The artificial intelligence (AI) company was up by nearly 9% in late-session trading, a rate that was easily topping the 0.8% rise of the S&P 500 (SNPINDEX: ^GSPC) . Follow the leader That news was the quarterly results posted after market hours Wednesday by leading graphics card processor company Nvidia , whose cutting-edge hardware products are widely used in the burgeoning AI industry . Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Happily for that industry -- not to mention its shareholders -- Nvidia did very well in the third quarter of its fiscal 2025. It managed to nearly double its already considerable revenue on a year-over-year basis, to more than $35 billion, and somehow top that with a 103% improvement in per-share net income (which hit $0.81). Both figures were comfortably above the consensus analyst estimates. This positively affects SoundHound AI in two important ways. One, it clearly illustrates that there's more than enough demand for AI functionalities of all kinds to sustain companies supplying the hardware that makes the tech possible. Second, and more directly, Nvidia is an investor in SoundHound AI; as of Sept. 30, the former company owned more than 1.7 million shares of the latter. Agents of change That happy development with Nvidia's results wasn't the only reason the market was sweet on SoundHound AI Thursday -- the company had some good news of its own to report. That morning, it said in a press release that its AI "agents" had assisted one of its clients, insurer Apivia Courtage, in helping more than 100,000 customer inquiries. SoundHound AI added that this had reduced by 20% the number of inbound requests handled by Apivia's customer relations specialists. Both of these developments were unambiguously positive for SoundHound AI, and should boost the company's profile. Just now, it isn't considered one of the more impactful or influential AI businesses on the market. Don’t miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $378,269 !* Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,369 !* Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $476,653 !* Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon. See 3 “Double Down” stocks » *Stock Advisor returns as of November 18, 2024 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy . Why SoundHound AI Stock Was Racing Higher on Thursday was originally published by The Motley Fool

Smith scores 23 in Furman's 69-63 win against Princeton

WASHINGTON (AP) — President-elect Donald Trump's incoming administration is set to be less diverse than President Joe Biden's administration, but several people of color and women appear likely to serve in top roles. While Trump vigorously campaigned against diversity and inclusion efforts in business and government, his Cabinet selections and other high-profile staffing choices include some barrier-breaking nominations. The Cabinet, if confirmed, is set to be one-third women and include some historic firsts. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.

3 Cult-Classic Sega Games Are Coming Back in New Collection

The world has long been captivated by Silicon Valley: the land of endless innovation, where founders start in garages and build tech giants. It is a formula that many have tried to emulate, but it's time for Dhaka to write its own recipe—one that works for our unique context, strengths, and challenges. The allure of Silicon Valley is undeniable. But when we try to replicate this formula in Bangladesh, we quickly learn that Dhaka isn't Palo Alto, and it doesn't have to be. Dhaka has its own rhythm, strengths, and potential. We are a city bursting with energy, full of entrepreneurs who innovate out of necessity. We do not need another Silicon Valley: we need a Dhaka Valley. To create the Dhaka Valley Recipe, we must embrace our context. In Bangladesh, startup founders don't have access to abundant venture capital or deep talent pools. Instead, we scale through resourcefulness, frugality, and community. When funding is sparse, we need to become profitable faster. When talent is scarce, we need to invest in people and focus on turning potential into excellence. Our founders often wear multiple hats—from sales to HR to operations and product management—roles that would be divided among many in Silicon Valley. This necessity breeds a kind of leadership that is nimble, empathetic, and deeply connected to the realities on the ground, making our founders agile and uniquely effective leaders. A key ingredient of the Dhaka Valley Recipe is managing growth and ensuring sustainability. We cannot afford to fail before attracting large foreign investors. This means carefully managing growth and creating a solid foundation that draws global interest. Bangladesh often falls at the bottom of investors' priority lists (even within emerging markets), so our funding funnel must adapt accordingly. The power of collaboration is also critical. In Silicon Valley, competition is often the driving force. Here, the power lies in collaboration—not just among founders but with customers, government bodies, and educational institutions. Our success stories are rooted in ecosystems where everyone benefits. We must also embrace our people-centric approach. Silicon Valley focuses heavily on technology, often with a "move fast and break things" mindset. In Dhaka, we must focus on people—on the communities we serve, on the employees we nurture, and on the families we impact. The work we do must create real value for people's lives. Empowerment is not just a buzzword; it is the foundation of our businesses—one that can lift millions from informal, unrecognised work into structured and sustainable livelihoods. Our growth in Bangladesh must be sustainable and inclusive. We cannot build for a handful while leaving millions behind. Instead, our growth must bring real economic change to those who need it most. Finally, we need to understand the dynamics of attracting venture capital. Venture capitalists need a return, and they are willing to make bold decisions if your business shows extraordinary potential to become a billion-dollar enterprise. We need to give them confidence that they can expect 10-20X returns—so that even in the worst-case scenario, they see a 2-3X return. The Dhaka Valley Recipe isn't about abandoning Silicon Valley's inspiration; it's about adapting it. Our challenges are different, and so are our strengths. We need solutions that work in our soil, crafted with our own ingredients. We need policymakers who foster innovation, investors who value impact, and founders who believe in this country's potential. If we can do that, we won't just create startups; we will create stories, change lives, and build an ecosystem future generations will be proud of. It's time for Dhaka to stop chasing the Silicon Valley dream and start living on its own. The writer is the founder and CEO of Sheba Platform Limited

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: Adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-ALL during the consolidation phase of multiphase therapy. CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1% in adults and pediatric patients one month or older. Relapsed or refractory CD19-positive B-ALL in adults and pediatric patients one month or older. In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: Adults with Philadelphia chromosome-negative CD19-positive relapsed or refractory B-ALL. Patients with Philadelphia chromosome-positive B-ALL should have failed treatment with at least two tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Adults with Philadelphia chromosome-negative CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1%. Pediatric patients aged 1 year or older with Philadelphia chromosome-negative CD19-positive B-ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. Pediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome-negative CD19-positive B-ALL as part of the consolidation therapy. BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® and treat with corticosteroids as recommended. Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® as recommended. Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Cytokine Release Syndrome (CRS): CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO ® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO ® , CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO ® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO ® until CRS resolves. Discontinue BLINCYTO ® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS. Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome: BLINCYTO ® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO ® treatment. The most common (≥ 10%) manifestations of neurological toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO ® , but some resulted in treatment discontinuation. The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO ® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO ® therapy. Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO ® as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities. Infections: Approximately 25% of patients receiving BLINCYTO ® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO ® as needed. Tumor Lysis Syndrome (TLS), which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used during BLINCYTO ® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO ® as needed to manage these events. Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO ® infusion and interrupt BLINCYTO ® if prolonged neutropenia occurs. Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO ® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO ® is being administered. Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO ® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO ® , although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO ® treatment. BLINCYTO ® treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN. Pancreatitis: Fatal pancreatitis has been reported in patients receiving BLINCYTO ® in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO ® and dexamethasone as needed. Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO ® , especially in patients previously treated with cranial irradiation and antileukemic chemotherapy. Preparation and administration errors have occurred with BLINCYTO ® treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose). Immunization: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO ® treatment, during treatment, and until immune recovery following last cycle of BLINCYTO ® . Benzyl Alcohol Toxicity in Neonates: Serious adverse reactions, including fatal reactions and the "gasping syndrome," have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions, because they may be less able to metabolize benzyl alcohol. Use the preservative-free preparations of BLINCYTO ® where possible in neonates. When prescribing BLINCYTO ® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO ® (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway. Monitor neonatal patients receiving BLINCYTO ® (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO ® 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL. Embryo-Fetal Toxicity: Based on its mechanism of action, BLINCYTO ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO ® and for 48 hours after the last dose. Adverse Reactions The safety of BLINCYTO ® in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B-cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO ® in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea. Dosage and Administration Guidelines BLINCYTO ® is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm. It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose). INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy. Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission. Relapsed or refractory disease. Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References SOURCE Amgen

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His ...